Dusina, Alex
 Distribuzione geografica
Continente #
NA - Nord America 415
EU - Europa 246
AS - Asia 42
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 710
Nazione #
US - Stati Uniti d'America 414
SE - Svezia 97
IT - Italia 56
IE - Irlanda 26
FI - Finlandia 17
FR - Francia 17
CN - Cina 14
DE - Germania 13
IN - India 12
SG - Singapore 8
GB - Regno Unito 6
CI - Costa d'Avorio 4
PL - Polonia 4
IR - Iran 3
RO - Romania 3
HK - Hong Kong 2
MD - Moldavia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BE - Belgio 1
BR - Brasile 1
CA - Canada 1
CH - Svizzera 1
DK - Danimarca 1
ES - Italia 1
EU - Europa 1
RU - Federazione Russa 1
VN - Vietnam 1
Totale 710
Città #
Chandler 163
Ashburn 36
Dublin 24
Rome 21
New York 20
Milan 18
Helsinki 17
San Mateo 17
Boston 16
Princeton 16
Marseille 12
Wilmington 11
Singapore 8
Beijing 7
Los Angeles 5
Pune 5
Redwood City 5
Seattle 5
Abidjan 4
Warsaw 4
Andover 3
Bologna 3
Bremen 3
Cambridge 3
Fairfield 3
London 3
Nanjing 3
Woodbridge 3
Augusta 2
Brescia 2
Dearborn 2
Edinburgh 2
Las Vegas 2
Norwalk 2
Sacramento 2
Siena 2
Ann Arbor 1
Bend 1
Brussels 1
Bucharest 1
Chicago 1
Chisinau 1
Copenhagen 1
Dong Ket 1
Florence 1
Fuzhou 1
Granada 1
Guangzhou 1
Hefei 1
Jiaxing 1
Kaohsiung City 1
Kashan 1
Kish 1
Munich 1
Phoenix 1
Riano 1
São Paulo 1
Taipei 1
Toronto 1
Zanjan 1
Zurich 1
Totale 479
Nome #
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 68
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 67
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 63
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 53
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 48
SARS-CoV-2 infection in a highly experienced person living with HIV 47
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 47
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 46
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 45
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 43
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 38
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 34
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 33
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 29
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 24
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine-Dolutegravir 24
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 24
Totale 733
Categoria #
all - tutte 3.860
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.860


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 9 0 0 0 0 1 1 1 1 2 9 0
2020/202136 1 0 0 0 1 0 8 0 3 14 4 5
2021/2022114 1 1 0 7 0 2 10 22 5 5 15 46
2022/2023412 49 62 19 60 33 45 22 46 45 4 26 1
2023/2024147 13 40 0 17 8 34 15 6 5 9 0 0
Totale 733